Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2017, Article ID 2372135, 8 pages
https://doi.org/10.1155/2017/2372135
Research Article

Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma

1Clinical Outcomes Solutions, Tucson, AZ, USA
2Purple Squirrel Economics, New York, NY, USA
3Eisai Ltd., Hertfordshire, UK
4UT Southwestern Medical Center, Dallas, TX, USA
5Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands

Correspondence should be addressed to Stacie Hudgens; moc.snoitulostuonilc@snegduh.eicats

Received 16 December 2016; Accepted 13 March 2017; Published 23 April 2017

Academic Editor: Peter C. Ferguson

Copyright © 2017 Stacie Hudgens et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. Soft Tissue Sarcoma (STS) is a rare malignancy of mesodermal tissue, with international incidence estimates between 1.8 and 5 per 100,000 per year. Understanding quality of life (QoL) and the detrimental impact of disease progression is critical for long-term care and survival. Objectives. The primary objective was to explore the relationship between disease progression and health-related quality of life (HRQoL) using data from Eisai’s study (E7389-G000-309). Methods. This was a 1 : 1 randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin versus dacarbazine in patients with advanced STS. The QoL analysis was conducted for the baseline and progression populations using the European Organization for Research and Treatment of Cancer 30-item core QoL questionnaire (EORTC QLQ-C30). Results. There were no statistical differences between the two treatment arms at baseline for any domain (; ). Of the 399 patients who experienced disease progression (unadjusted and adjusting for histology), dacarbazine patients had significantly lower Global Health Status, Physical Functioning scores, and significantly worse Nausea and Vomiting, Insomnia, and Appetite Loss (). Conclusions. These results indicate differences in HRQoL overall and at progression between dacarbazine and eribulin patients, with increases in symptom severity observed among dacarbazine patients.